2026-07-18

India’s pharmaceutical evolution has been a remarkable journey, from building manufacturing strength to emerging as a global provider of cost-effective medicines. Currently, exports transcend USD 30 billion each year, demonstrating both the scale and the international trust in India’s health care capabilities. This achievement has set the stage for the next chapter of the industry. With the global health care needs becoming more intricate and aligned with innovation, the possibilities are expanding. This isn’t a departure from what India does best; it’s simply a logical next step. The same ecosystem that made affordable production possible, because of a talented workforce, solid regulations, and supportive policies, is now poised to fuel research-driven expansion. This shift isn’t about abandoning what has worked; rather, it’s about refining it to uncover greater value and a more profound global impact.

From Scale to Value: The Next Growth Curve
India’s pharmaceutical industry ranks among the top globally by volume, supplying nearly 20 percent of the world’s generic medicines and serving about 200 countries. However, in value terms, the disparity remains huge. While the domestic market is currently valued at around USD 60 billion and is expected to reach USD 120-130 billion by 2030, much of this growth risks remaining volume-driven unless supported by innovation.

High-margin, long-lifecycle segments such as biologics, speciality drugs, and precision therapies are redefining global pharmaceutical markets, driving policymakers to realign frame works in favor of innovation and research-led expansion. As this transition accelerates, regulatory landscapes are shifting to champion a research-led future. Schemes such as Biopharma Shakti and Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), with INR 10,000 crore and INR 5,000 crore, respectively, work to utilise capital for novel therapies, biologics as well as sophisticated generics.

Yet, realising meaningful innovation from this policy will demand stronger practical efforts. The drug discovery process is both costly and risky, with extended development cycles that can significantly constrain private sector participation. As a result, strengthening and expanding incentive frameworks to make them more accessible and commercially attractive will be critical in allowing companies to invest more confidently in research and development (R&D) and sustain long-term innovation.

This change indicates a transition from price-based competition toward value-driven excellence and robust Intellectual Property (IP) development.

Rising Disease Burden, Rising Need for Innovation
A structural shift is underway in India’s health care industry. By 2030, the nation is estimated to have more than 79.4 million diabetes cases along with an increasing burden of cancer, cardiovascular and autoimmune diseases. These conditions require long-term, specialised, and often personalised treatments, areas where innovation becomes critical.

Relying on imported therapies for such conditions creates both cost and access challenges. For many Indian families, the cost of care remains a heavy personal responsibility. Consequently, locally developed therapies can promise a path to make treatment more affordable and widely accessible.

At the same time, India’s specific disease burdens and patient profiles differ from international markets, demanding locally tailored medical breakthroughs. Expanding footprints, such as the 18,646+ Jan Aushadhi Kendras (JAKs), have bridged the delivery gap. Nonetheless, localised innovation remains the missing piece for sustainable affordability. Investing in novel discovery guarantees that future health care will be both economically accessible and specifically optimised for India’s needs.

In this context, India’s traditional medicine systems present a complementary opportunity, particularly for conditions requiring long-term management. However, for these therapies to gain global acceptance and clinical credibility, they must undergo rigorous scientific validation via structured trials, standardisation as well as evidence-based evaluation.

Building on this, integrating plant-based knowledge with modern drug development and manufacturing can enable the creation of scientifically validated formulations that are both globally acceptable and commercially viable, offering India a differentiated pathway in innovation.

Developing an Innovation-Ready Ecosystem
India possesses the essential components for a world-class drug discovery ecosystem. With a vast network of international-standard manufacturing facilities and a deep pool of scientific talent, the nation provides a cost-efficient R&D landscape. This creates the groundwork for pioneering research and the long-term development of innovative global therapies.

However, in order to fully leverage this foundation, structural gaps must be addressed. This particularly includes the limited collaboration between academic institutions and the pharmaceutical industry. While institute-led research remains largely academic, insufficient emphasis on commercialisation limits the translation of findings into real-world therapies. Enhancing industry-research linkages and aligning studies with market needs will be key to driving tangible outcomes.

Even as India produces a vast pool of scientific talent, many Indian-origin researchers continue to contribute to leading breakthroughs in global institutions. This highlights the need for a more competitive domestic ecosystem, with stronger funding, infrastructure, and career pathways to retain and effectively utilise this talent.

Additionally, Indian manufacturers have exhibited significant technical depth in intricate antibiotic formulations for the national and international markets, a foundation that can be extended to advanced therapeutics. Supporting the ecosystem, policy initiatives are delivering measurable impact: PLI schemes have prevented Active Pharmaceutical Ingredients (API) imports worth INR 3,592 crore. On the other hand, regulatory reforms and a planned expansion to over 1,000 clinical trial sites are shortening approval timelines and supporting comprehensive end-to-end drug development.

Further strengthening this ecosystem will require deeper integration between public research institutions such as Council of Scientific and Industrial Research (CSIR), Defence Research and Development Organisation (DRDO), Indian Space Research Organisation (ISRO), Indian Council of Agricultural Research (ICAR) and Indian Council of Medical Research (ICMR) and the pharmaceutical industry. Enabling structured industry participation in their research, through joint development and translational programs, can significantly accelerate innovation and improve commercial outcomes.

Meanwhile, trends in Contract Development and Manufacturing Organisations (CDMOs) and Contract Research Organisations (CROs) are reinforcing India’s emergence as a strategic partner in global drug development. Achieving scalable innovation will depend on enhanced collaboration between academic institutions and industry, together with the focus shifted from discovery alone to market-ready therapies.

A Defining Opportunity for Global Leadership
India’s pharmaceutical sector has already demonstrated its ability to deliver at scale. The next phase will be defined by its ability to create. As global health care moves toward more complex and personalised treatments, value will increasingly be captured by those who innovate.

The foundations are already in place: strong manufacturing, policy support, scientific talent, and growing investment in R&D. What is needed now is sustained focus and scale in novel drug discovery.

This is not merely an industry evolution. Instead, it is a strategic lever. By shifting from volume to value, India can strengthen its global footprint, increasing both access to medicines and its influence over the future direction of pharmaceutical innovation.